换一批Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
第一作者：
Eugenio,Gaudio
第一单位：
Lymphoma and Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland.
作者：
医学主题词
乙酰苯胺类(Acetanilides);腺嘌呤(Adenine);动物(Animals);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞系, 肿瘤(Cell Line, Tumor);药物协同作用(Drug Synergism);杂环化合物, 3环(Heterocyclic Compounds, 3-Ring);组蛋白脱乙酰基酶抑制剂(Histone Deacetylase Inhibitors);人类(Humans);羟肟酸类(Hydroxamic Acids);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);小鼠(Mice);小鼠, 近交NOD(Mice, Inbred NOD);小鼠, SCID(Mice, SCID);分子靶向治疗(Molecular Targeted Therapy);哌啶类(Piperidines);蛋白激酶抑制剂(Protein Kinase Inhibitors);蛋白酪氨酸激酶类(Protein-Tyrosine Kinases);吡唑类(Pyrazoles);嘧啶类(Pyrimidines);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.18632/oncotarget.10983
PMID
27494885
发布时间
2022-03-21
- 浏览3
Oncotarget
58142-58147页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
